Jinjian LU 陸金健

• Journal Contributions

Dr. Lu has published more than 200 scientific papers in the SCI journals, such as Journal of Hematology & Oncology, Pharmacology & Therapeutics, Redox Biology, Acta Pharmaceutica Sinica B, etc. (Total Citations 10000+, h index=57, google scholar). Please click here for the full publications.

https://www.researchgate.net/profile/Jin-Jian_Lu

https://scholar.google.com/citations?user=G7DwcegAAAAJ&hl=en

Representative publications in recent years (*Corresponding or co-corresponding author)

1. Xu CC, Lin YF, Huang MY, Zhang XL, Wang P, Huang MQ*, Lu JJ*. Paraptosis: a non-classical paradigm of cell death for cancer therapy. Acta Pharmacologica Sinica. 2024, 45(2): 223-237.
2. Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, He XL, Chen X, Chen X, Zhang B, Kai G, Zhang X, Li T*, Huang M*, Lu JJ*. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacological Research. 2023, 106988.
3. Ye ZH, Yu WB, Huang MY, Chen J, Lu JJ*. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B. 2023, 13(4): 1467-87.
4. Yu WB, Chen YC, Huang CY, Ye ZH, Shi W, Zhu H, Shi JJ, Chen J, Lu JJ*. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. Frontiers of Medicine. 2023, 17(1): 105-118.
5. Xu YL, Yuan LW, Jiang XM, Su MX, Huang MY, Chen YC, Zhang LL, Chen X, Zhu H, Lu JJ*. Glutathione peroxidase 8 expression on cancer cells and cancer-associated fibroblasts facilitates lung cancer metastasis. MedComm. 2022, 3(3): e152.
6. Chen YC, HE XL, Qi L, Shi W, Yuan LW, Huang MY, Xu YL, Chen X, Gu L, Zhang LL, Lu JJ*. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells. Biochemical Pharmacology. 2022, 197: 114940.
7. Su MX, Xu YL, Jiang XM, Huang MY, Zhang LL, Yuan LW, Xu XH, Zhu Q, Gao JL, Lu JH, Chen X, Huang MQ, Wang Y, Lu JJ*. c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2. Acta Pharmaceutica Sinica B. 2022, 12(3): 1240-53.
8. Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ*. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacology & Therapeutics. 2021, 219: 107694.
9. Ye ZH, Jiang XM, Huang MY, Xu YL, Chen YC, Yuan LW, Huang CY, Yu WB, Chen X, Lu JJ*. Regulation of CD47 expression by interferon-gamma in cancer cells. Translational Oncology. 2021, 14: 101162.
10. Yuan LW, Jiang XM, Xu YL, Huang MY, Chen YC, Yu WB, Su MX, Ye ZH, Chen X, Wang Y, Lu JJ*. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Phytomedicine. 2021, 80: 153394.
11. Yu WB, Ye ZH, Chen X, Shi JJ*, Lu JJ*. The development of small-molecule inhibitors targeting CD47. Drug Discovery Today, 2021, 26(2): 561-68.
12. Jiang XM, Xu YL, Yuan LW, Zhang LL, Huang MY, Ye ZH, Su MX, Chen X, Zhu H, Ye R, Lu JJ*. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. Acta Pharmacologica Sinica. 2021, 42: 451-9.
13. Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ*. Activation of Notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. Biochemical Pharmacology. 2020, 175: 113921.
14. Zhang LL, Guo J, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, Li H*, Lu JJ*. Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity. Acta Pharmacologica Sinica. 2020, 41: 698-705.
15. Huang MY, Jiang XM*, Xu YL, Yuan LW, Chen YC, Cui G, Huang RY, Liu B, Wang Y, Chen X, Lu JJ*. Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells. Food and Chemical Toxicology. 2019, 131: 110537.
16. Zhang LL, Jiang XM, Huang MY, Feng ZL, Chen X, Wang Y, Li H, Li A, Lin LG*, Lu JJ*. Nagilactone E suppresses TGF-β1-induced epithelial–mesenchymal transition, migration and invasion in non-small cell lung cancer cells. Phytomedicine. 2019, 52: 32-9.
17. Cao WX, Li T, Tang ZH, Zhang LL, Wang ZY, Guo X, Su MX, Chen X, Lu JJ*. MLKL mediates apoptosis via a mutual regulation with PERK/eIF2α pathway in response to reactive oxygen species generation. Apoptosis. 2018, 23(9-10): 521-31.
18. Li T, Jiang HL, Tong YG, Lu JJ*. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. Journal of Hematology & Oncology. 2018, 11: 59.
19. Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, Lu JJ*. Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. Cancer Letters. 2018, 412: 1-9.
20. Tang ZH, Lu JJ*. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Letters. 2018, 420: 242-6.

Book Chapters

• Pharmacology. China Science Publishing & Media LTD. ISBN: 978-7-03-075287-1. August 2023.
• Essay Writing in Pharmacy and Pharmaceutical Science. People’s Medical Publishing House Co. LTD. ISBN: 978-7-117-29706-6. January
• Pharmacology in Chinese medicines (3^rd Edition). Shanghai Scientific & Technical Publishers. ISBN: 978-7-5478-4239-3/R·1738. January 2019.
• Advances of Chinese medicines for cancer therapy. People’s Medical Publishing House Co. LTD. ISBN: 978-7-117-16227-2/R·16228. October, 2012.